A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test how long participants with colorectal cancer live
without progressive disease when being treated with IMC-1121B (ramucirumab) and the modified
FOLFOX-6 chemotherapy.